Luis Caminal

Internal Medicine. Bedside-medicine.
Systemic Autoimmune Diseases.
Can't walk away from life's work and passion.

[Luis Caminal @caminalm]

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica | New England Journal of Medicine https://t.co/d9YfS67YtY

[Luis Caminal @caminalm]

Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting | New England Journal of Medicine https://t.co/hJuNIp9Y3j

[NEJM @NEJM]

Presented at #EULAR2026:

In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. Full INDIGO trial results: https://t.co/Lynf6nmA9N

Editorial: Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease https://t.co/BUQ7r8jVWz

@eular_org

[Luis Caminal @caminalm]

IL-5, eosinophils and IL-5 pathway inhibitors in # EGPA . https://t.co/jQOEO6sHJN

[Luis Caminal @caminalm]

Statins for primary prevention of cardiovascular disease in patients without diabetes?https://t.co/6QqNMmj5Ya

[NEJM @NEJM]

Correspondence: Dulaglutide-Associated Choroidal Lymphoid Hyperplasia https://t.co/E7IZNZNduk

#Endocrinology #Ophthalmology

[Giuseppe Galati @GiuseppeGalati_]

🗞️ Current state of knowledge on the
epidemiology, aetiology, diagnosis, &
management of heart involvement in
eosinophilia.
Consensus Statement of @escardio WG on Myocardial & Pericardial D.

🫀Heart involvement in eosinophilia represents a rare disease associated with a wide range of clinical manifestations and a broad spectrum of underlying aetiologies.

✅Early detection of heart involvement associated with HE & identifying the cause of eosinophilia is of utmost importance to initiate appropriate treatment and prevent deleterious
heart damage leading to poor outcomes.

🤝A multidisciplinary approach for the management of affected individuals with EHD is needed.

🫀 @HFUAcademy 🍀

https://t.co/0dFvFm9NeT

@EJHFEiC
@AmrAbdin10 @KTamirisaMD @DrRajivsankar @JBauersachsMD @robmentz @TomLuscher @AndrewJSauer
@DrMarthaGulati @FedericaFogacci @afgcicero @LuPoten @glimongelli @IacopoOlivotto @HanCardiomd
@GMCRosano @EJHFEiC @SeguraCardio @ShelleyZieroth @chiarabd @iamritu @cristinagavina @FeliceGragnano @rahatheart1 @gpontone1 @stefanocarugo @AnastasiaSMihai @radcliffeCARDIO @gcfm

https://t.co/d2cux2uE4x

[Eric Topol @EricTopol]

We've written about AI-induced physician deskilling that has already surfaced
https://t.co/iMy6zyWnhZ @tberzin
AI-induced never-skilling among newly trained doctors, while not yet proven, is a serious concern that needs to be addressed @NatureMedicine @nliulab
https://t.co/yov3YvsGti

[JCR: Journal of Clinical Rheumatology @JRheumatology]

Off-label Use of Nemolizumab to Address Pruritic Skin Disease: A Case Series in DM Patients
✨Rapid improvement in refractory pruritus and cutaneous disease activity in a case series of 5 dermatomyositis patients.
No serious adverse events observed. 📖
https://t.co/YT4mxSn76x

[Jerome HADJADJ @HadjadjJerome]

A retrospective, real-world study of IV iron use to treat iron deficiency anemia during acute infection
https://t.co/D4rMw19U3E

[Luis Caminal @caminalm]

Spectrum and significance of 18 F-FDG-PET/CT abnormalities in #VEXAS syndrome https://t.co/sLTXr8CRnC

[The BMJ @bmj_latest]

"Guidelines should help clinicians and patients make better decisions, but too often they do the opposite."

Overcoming ambiguous guideline recommendations
https://t.co/n1aMdDR2FI

[JCR: Journal of Clinical Rheumatology @JRheumatology]

🔬 Real-world study
Isolated Anti-SSB vs combined Anti-SSA and Anti-SSB
315 patients
Found isolated anti-SSB + was associated with ⬇️ rates of Sjögren disease, SLE, RA, xerophthalmia, and autoantibody positivity compared with combined anti-SSA/SSB abs
https://t.co/u8crzBuOTn

[Dr. John Cush @RheumNow]

FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/qqPsjhUClP

[Oxford Medical Case Reports @OxfordMedicalCR]

Uncommon alliance between MOGAD and Behçet's disease
https://t.co/nU5qdV4KC5
#casereport

[Luis Caminal @caminalm]

Changing patterns in hospitalisations of patients with # SLE over three decades at a tertiary referral centre in Catalonia. https://t.co/qhBSqBOmxR #ScholarAlerts

[Luis Caminal @caminalm]

Triple autoantibody-seronegative patients with # systemic sclerosis https://t.co/xRNFd5fLvf

[Luis Caminal @caminalm]

Management of ANCA-Associated Alveolar Hemorrhage: A Bayesian Reanalysis of the PEXIVAS Trial https://t.co/Lz8ybKO0DD

[Luis Caminal @caminalm]

From Serendipity to Science: How #Anti-HMGCR Antibodies Changed Our Understanding of Myositis https://t.co/xhKGAsBNZs

[Luis Caminal @caminalm]

Inflammatory Myopathies | New England Journal of Medicine https://t.co/j0IJOrDfqe